FDA Grants Diazyme 510(k) Clearance to Market Its D-Dimer Assay for Clinical Chemistry Analyzers
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 02/12/13 -- Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its D-Dimer assay. In line with current clinical needs, Diazyme's D-Dimer latex-enhanced immunoturbidimetric assay can be utilized to measure total levels of D-Dimer in plasma samples as part of a work up of patients with blood clotting issues. Utilization of this technology allows for highly reliable and precise test results, with minimal sample volumes. The D-Dimer assay is both fast and flexible with complete test results in minutes. Furthermore, the assay has been designed to work on most high throughput clinical chemistry analyzers, allowing users faster results and improved laboratory workflow.
Diazyme's D-Dimer assay is an important new tool to aid in detecting the presence of intravascular coagulation and fibrinolysis. By quantitatively determining the concentration of the clotting proteins such as fibrinogen and fibrin degradation products (D-Dimer) in human plasma, Diazyme's new assay can assist in the evaluation of patients with abnormal clotting.
"Diazyme's D-Dimer assay provides a precise, flexible and cost effective test method for laboratories of virtually all sizes," said Dr. Chong Yuan, Managing Director of Diazyme Laboratories. "The sensitivity of the assay allows D-Dimer levels to be measured very efficiently and effectively."
Diazyme Laboratories is a division of General Atomics headquartered in La Jolla, California. Diazyme uses its enzyme platform technologies to develop innovative assays for clinical and research uses with reduced costs and improved performance. Products include diagnostic blood tests for cardiac markers, diabetes, nutritional assessment, liver disease, renal disease and electrolytes. Information regarding Diazyme's enzyme technology and related products can be found on its website at .
Diazyme Laboratories:
Douglas Borses
860-729-0121
Public Relations:
Doug Fouquet
(858) 455-2173
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.02.2013 - 21:05 Uhr
Sprache: Deutsch
News-ID 228822
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"FDA Grants Diazyme 510(k) Clearance to Market Its D-Dimer Assay for Clinical Chemistry Analyzers"
steht unter der journalistisch-redaktionellen Verantwortung von
General Atomics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
